Companies that are involved in the manufacture or supply of medicines in the UK need to have the relevant licence for the activity in question. This note explains how medicines regulation now extends to the entire supply chain for medicinal products, and imposes rigorous standards on medicines manufacturers and wholesale dealers who trade in them, as well as brokers who negotiate sales. Note: the regulations discussed in this note may be subject to change after the expiry of the transition period that follows the UK’s exit from the EU on 31 January 2020. The transition period currently expires on 31 December 2020, but may be extended.
This content is restricted to members. To view this content please register or login below to view this content.
